Nanomedicine, Volume IIA: Biocompatibility

© 2003 Robert A. Freitas Jr. All Rights Reserved.

Robert A. Freitas Jr., Nanomedicine, Volume IIA: Biocompatibility, Landes Bioscience, Georgetown, TX, 2003


References 3200-3299

3200. R. Johnson, D. Harrison, M. Tucci, A. Tsao, M. Lemos, A. Puckett, J.L. Hughes, H. Benghuzzi, “Fibrous capsule formation in response to ultrahigh molecular weight polyethylene treated with peptides that influence adhesion,” Biomed. Sci. Instrum. 34(1997):47-52.

3201. I. Gotman, “Characteristics of metals used in implants,” J. Endourol. 11(December 1997):383-389.

3202. P. Asperberg, S.B. Goodman, J.S. Wang, “Influence of callus deformation time. Bone chamber study in rabbits,” Clin. Orthop. 322(January 1996):253-261.

3203. P. Aspenberg, P. Herbertsson, “Periprosthetic bone resorption. Particles versus movement,” J. Bone Joint Surg. Br. 78(July 1996):641-646.

3204. M. Jasty, C.R. Bragdon, D. Burke, D. O’Connor, J.D. Lowenstein, W.H. Harris, “In vivo skeletal responses to porous-surfaced implants subjected to small induced motions,” J. Bone Joint Surg. Am. 79(May 1997):707-714.

3205. B.D. Schmit, J.T. Mortimer, “The tissue response to epimysial electrodes for diaphragm pacing in dogs,” IEEE Trans. Biomed. Eng. 44(October 1997):921-930.

3206. K. Soballe, S. Overgaard, E.S. Hansen, H. Brokstedt-Rasmussen, M. Lind, C. Bunger, “A review of ceramic coatings for implant fixation,” J. Long Term Eff. Med. Implants 9(1999):131-151.

3207. C.R. Bragdon, D. Burke, J.D. Lowenstein, D. O’Connor, B. Ramamurti, M. Jasty, W.H. Harris, “Differences in stiffness of the interface between a cementless porous implant and cancellous bone in vivo in dogs due to varying amounts of implant motion,” J. Arthroplasty 11(December 1996):945-951.

3208. D.F. Williams, R. Roaf, Implants in Surgery, W.B. Saunders Company Ltd., London, 1973.

3209. L.F.V. Vincent, Structural Biomaterials, Revised Edition, Princeton University Press, Princeton, New Jersey, 1990.

3210. F.H. Silver, Y.P. Kato, M. Ohno, A.J. Wasserman, “Analysis of mammalian connective tissue: relationship between hierarchical structures and mechanical properties,” J. Long Term Eff. Med. Implants 2(1992):165-198.

3211. J.A. Szivek, E.M. Johnson, F.P. Magee, J. Emmanual, R. Poser, J.B. Koeneman, “Bone remodeling and in vivo strain analysis of intact and implanted greyhound proximal femora,” J. Invest. Surg. 7(May-June 1994):213-233.

3212. N.K. Wood, E.J. Kaminski, R.J. Oglesby, “The significance of implant shape in experimental testing of biological materials: disc vs. rod,” J. Biomed. Mater. Res. 4(March 1970):1-12.

3213. G.A. Ksander, L.M. Vistnes, “The incidence of experimental contracture varies with the source of the prosthesis,” Plast. Reconstr. Surg. 75(May 1985):668-676.

3214. D. Greene, L. Pruitt, C.S. Maas, “Biomechanical effects of e-PTFE implant structure on soft tissue implantation stability: a study in the porcine model,” Laryngoscope 107(July 1997):957-962.

3215. C.S. Zhu, K. Ohsaki, K. Li, Q. Ye, Y.H. Tran, Y. Ohba, K. Moriyama, “Long-term observation of subcutaneous tissue reaction to synthetic auditory ossicle (bioceram) in rats,” J. Med. Invest. 46(February 1999):97-103.

3216. B.F. Matlaga, L.P. Yasenchak, T.N. Salthouse, “Tissue response to implanted polymers: the significance of sample shape,” J. Biomed. Mater. Res. 10(May 1976):391-397.

3217. R.K. Shepherd, J. Matsushima, R.L. Martin, G.M. Clark, “Cochlear pathology following chronic electrical stimulation of the auditory nerve: II. Deafened kittens,” Hear. Res. 81(December 1994):150-166.

3218. J.M. Akers, P.H. Packham, M.W. Keith, K. Merritt, “Tissue response to chronically stimulated implanted epimysial and intramuscular electrodes,” IEEE Trans. Rehabil. Eng. 5(June 1997):207-220.

3219. P.J. Rousche, R.A. Normann, “Chronic recording capability of the Utah Intracortical Electrode Array in cat sensory cortex,” J. Neurosci. Methods 82(1 July 1998):1-15.

3220. P.P. Karpawich, K.B. Stokes, K. Proctor, R. Schallhorn, R. McVenes, “In-line bipolar, steroid-eluting, high impedance, epimyocardial pacing lead,” Pacing Clin. Electrophysiol. 21(March 1998):503-508.

3221. W.J. Peters, D.C. Smith, “Ivalon breast prostheses: evaluation 19 years after implantation,” Plast. Reconstr. Surg. 67(April 1981):514-518.

3222. N. Chegini, J.A. von Fraunhofer, D.L. Hay, B.J. Masterson, “Tissue reactions to absorbable ligating clips,” J. Reprod. Med. 33(February 1988):187-192.

3223. T.G. Heaney, P.J. Doherty, D.F. Williams, “Marsupialization of percutaneous implants in presence of deep connective tissue,” J. Biomed. Mater. Res. 32(December 1996):593-601.

3224. A.F. von Recum, “Applications and failure modes of percutaneous devices: a review,” J. Biomed. Mater. Res. 18(April 1984):323-336.

3225. L. Linder, T. Albrektsson, P.I. Branemark, H.A. Hansson, B. Ivarsson, U. Jonsson, I. Lundstrom, “Electron microscope analysis of the bone-titanium interface,” Acta Orthop. Scand. 54(February 1983):45-52.

3226. J. Lassus et al, “Macrophage activation results in bone resorption,” Clin. Othop. 352(July 1998):7-15.

3227. W.A. Scott, N.A. Pawlowski, E.B. Cramer, Z.A. Cohn, “Secretory functions of the mononuclear phagocyte,” Adv. Exp. Med. Biol. 183(1985):17-25.

3228. G. Camussi, F. Bussolino, C. Tetta, W. Piacibello, M. Aglietta, “Biosynthesis and release of platelet-activating factor from human monocytes,” Int. Arch. Allergy Appl. Immunol. 70(March 1983):245-251.

3229. F. Bazzoni, M.A. Cassatella, F. Rossi, M. Ceska, B. Dewald, M. Baggiolini, “Phagocytosing neutrophils produce and release high amounts of the neutrophil-activating peptide 1/interleukin 8,” J. Exp. Med. 173(1 March 1991):771-774.

3230. E.J. Leonard, A. Skeel, T. Yoshimura, J. Rankin, “Secretion of monocyte chemoattractant protein-1 (MCP-1) by human mononuclear phagocytes,” Adv. Exp. Med. Biol. 351(1993):55-64; A. Wuyts, P. Proost, W. Put, J.P. Lenaerts, L. Paemen, J. van Damme, “Leukocyte recruitment by monocyte chemotactic proteins (MCPs) secreted by human phagocytes,” J. Immunol. Methods 174(14 September 1994):237-247.

3231. J.E. Losa Garcia, F.M. Rodriguez, M.R. Martin de Cabo, M.J. Garcia Salgado, J.P. Losada, L.G. Villaron, A.J. Lopez, J.L. Arellano, “Evaluation of inflammatory cytokine secretion by human alveolar macrophages,” Mediators Inflamm. 8(1999):43-51.

3232. T.J. Lin, N. Hirji, G.R. Stenton, M. Gilchrist, B.J. Grill, A.D. Schreiber, A.D. Befus, “Activation of macrophage CD8: pharmacological studies of TNF and IL-1 beta production,” J. Immunol. 164(15 February 2000):1783-1792.

3233. M. von Der Ohe, J. Altstaedt, U. Gross, L. Rink, “Human neutrophils produce macrophage inhibitory protein-1beta but not type I interferons in response to viral stimulation,” J. Interferon Cytokine Res. 21(April 2001):241-247.

3234. K. Kamikawa, Y. Harada, K. Nagata, H. Moriya, “Differential effects of oxidized and non-oxidized polyethylene particles on human monocyte/macrophages in vitro,” J. Bone Joint Surg. Br. 83(May 2001):593-597.

3235. G.P. Smith, T.J. Peters, “The release of granule components from human polymorphonuclear leukocytes in response to both phagocytic and chemical stimuli,” Biochim. Biophys. Acta 719(24 November 1982):304-308.

3236. B. Hurlen, I. Olsen, E. Lingaas, T. Midtvedt, “Neutrophil phagocytosis of Treponema denticola as indicated by extracellular release of lactoferrin,” Acta Pathol. Microbiol. Immunol. Scand. B 92(June 1984):171-173.

3237. M. Bergenfeldt, L. Axelsson, K. Ohlsson, “Release of neutrophil proteinase 4(3) and leukocyte elastase during phagocytosis and their interaction with proteinase inhibitors,” Scand. J. Clin. Lab. Invest. 52(December 1992):823-829.

3238. L.M. Lichtenstein, G. Marone, L.L. Thomas, F.J. Malveaux, “The role of basophils in inflammatory reactions,” J. Invest. Dermatol. 71(July 1978):65-69.

3239. M. Wettstein, T. Peters-Regehr, R. Kubitz, R. Fischer, C. Holneicher, I. Monnighoff, D. Haussinger, “Release of osmolytes induced by phagocytosis and hormones in rat liver,” Am. J. Physiol. Gastrointest. Liver Physiol. 278(February 2000):G227-G233.

3240. C. Godson, S. Mitchell, K. Harvey, N.A. Petasis, N. Hogg, H.R. Brady, “Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages,” J. Immunol. 164(15 February 2000):1663-1667.

3241. A. Perianin, M.A. Gougerot-Pocidalo, J.P. Giroud, J. Hakim, “Diclofenac sodium, a negative chemokinetic factor for neutrophil locomotion,” Biochem. Pharmacol. 34(1 October 1985):3433-3438.

3242. K. Aoshiba, A. Nagai, Y. Ishihara, J. Kagawa, T. Takizawa, “Effects of alpha 1-proteinase inhibitor on chemotaxis and chemokinesis of polymorphonuclear leukocytes: its possible role in regulating polymorphonuclear leukocyte recruitment in human subjects,” J. Lab. Clin. Med. 122(September 1993):333-340.

3243. K.O. Holevinsky, D.J. Nelson, “Membrane capacitance changes associated with particle uptake during phagocytosis in macrophages,” Biophys. J. 75(November 1998):2577-2586.

3244. G.J. Randolph, K. Inaba, D.F. Robbiani, R.M. Steinman, W.A. Muller, “Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo,” Immunity 11(December 1999):753-761.

3245. L. Benov, I. Fridovich, “Escherichia coli exhibits negative chemotaxis in gradients of hydrogen peroxide, hypochlorite, and N-chlorotaurine: products of the respiratory burst of phagocytic cells,” Proc. Natl. Acad. Sci. (USA) 93(14 May 1996):4999-5002.

3246. M. Montrone, D. Oesterhelt, W. Marwan, “Phosphorylation-independent bacterial chemoresponses correlate with changes in the cytoplasmic level of fumarate,” J. Bacteriol. 178(December 1996):6882-6887.

3247. W. Shi, T. Kohler, D.R. Zusman, “Chemotaxis plays a role in the social behavior of Myxococcus xanthus,” Mol. Microbiol. 9(August 1993):601-611.

3248. M. Homma, H. Oota, S. Kojima, I. Kawagishi, Y. Imae, “Chemotactic responses to an attractant and a repellent by the polar and lateral flagellar systems of Vibrio alginolyticus,” Microbiology 142(October 1996):2777-2783.

3249. M.L. Kirsch, A.R. Zuberi, D. Henner, P.D. Peters, M.A. Yazdi, G.W. Ordal, “Chemotactic methyltransferase promotes adaptation to repellents in Bacillus subtilis,” J. Biol. Chem. 268(5 December 1993):25350-25356; G.W. Ordal, D.P. Villani, “Action of uncouplers of oxidative phosphorylation as chemotactic repellents of Bacillus subtilis,” J. Gen. Microbiol. 118(June 1980):471-478; G.W. Ordal, “Recognition sites for chemotactic repellents of Bacillus subtilis,” J. Bacteriol. 126(April 1976):72-79.

3250. B. Styrt, B. Sugarman, N. Mummaw, J.C. White, “Chemorepulsion of trichomonads by products of neutrophil oxidative metabolism,” J. Infect. Dis. 163(January 1991):176-179.

3251. B. Sugarman, N. Mummaw, “Effects of antimicrobial agents on growth and chemotaxis of Trichomonas vaginalis,” Antimicrob. Agents Chemother. 32(September 1988):1323-1326.

3252. T.M. Hennessey, M.Y. Kim, B.H. Satir, “Lysozyme acts as a chemorepellent and secretagogue in Paramecium by activating a novel receptor-operated Ca++ conductance,” J. Membr. Biol. 148(November 1995):13-25.

3253. J.T. Francis, T.M. Hennessey, “Chemorepellents in Paramecium and Tetrahymena,” J. Eukaryot. Microbiol. 42(January-February 1995):78-83.

3254. H.G. Kuruvilla, T.M. Hennessey, “Purification and characterization of a novel chemorepellent receptor from Tetrahymena thermophila,” J. Membr. Biol. 162(1 March 1998):51-57.

3255. S.R. Mace, J.G. Dean, J.R. Murphy, J.L. Rhodes, H.G. Kuruvilla, “PACAP-38 is a chemorepellent and an agonist for the lysozyme receptor in Tetrahymena thermophila,” J. Comp. Physiol. A 186(January 2000):39-43.

3256. L. Kohidai, P. Kovacs, G. Csaba, “Chemotactic response of unicellular Tetrahymena to a leukocyte attractant peptide and its repellent derivative: evolutionary conclusions,” Cell Biol. Int. 18(February 1994):119-122.

3257. Z. He, M. Tessier-Lavigne, “Neuropilin is a receptor for the axonal chemorepellent Semaphorin III,” Cell 90(22 August 1997):739-751.

3258. A. Elhabazi, V. Lang, C. Herold, G.J. Freeman, A. Bensussan, L. Boumsell, G. Bismuth, “The human semaphorin-like leukocyte cell surface molecule CD100 associates with a serine kinase activity,” J. Biol. Chem. 272(19 September 1997):23515-23520.

3259. M.D. Mark, M. Lohrum, A.W. Puschel, “Patterning neuronal connections by chemorepulsion: the semaphorins,” Cell Tissue Res. 290(November 1997):299-306.

3260. N. Miyazaki, T. Furuyama, M. Amasaki, H. Sugimoto, T. Sakai, N. Takeda, T. Kubo, S. Inagaki, “Mouse semaphorin H inhibits neurite outgrowth from sensory neurons,” Neurosci. Res. 33(April 1999):269-274.

3261. F. de Castro, L. Hu, H. Drabkin, C. Sotelo, A. Chedotal, “Chemoattraction and chemorepulsion of olfactory bulb axons by different secreted semaphorins,” J. Neurosci. 19(1 June 1999):4428-4436.

3262. B. Rohm, A. Ottemeyer, M. Lohrum, A.W. Puschel, “Plexin/neuropilin complexes mediate repulsion by the axonal guidance signal semaphorin 3A,” Mech. Dev. 93(May 2000):95-104.

3263. J.G. Culotti, A.L. Kolodkin, “Functions of netrins and semaphorins in axon guidance,” curr. Opin. Neurobiol. 6(February 1996):81-88.

3264. A. Varela-Echavarria, A. Tucker, A.W. Puschel, S. Guthrie, “Motor axon subpopulations respond differentially to the chemorepellents netrin-1 and semaphorin D,” Neuron 18(February 1997):193-207.

3265. G.L. Ming, H.J. Song, B. Berninger, C.E. Holt, M. Tessier-Lavigne, M.M Poo, “cAMP-dependent growth cone guidance by netrin-1,” Neuron 19(December 1997):1225-1235.

3266. F.J. Livesey, S.P. Hunt, “Netrin and netrin receptor expression in the embryonic mammalian nervous system suggests roles in retinal, triatal, nigral, and cerebellar development,” Mol. Cell. Neurosci. 8(1997):417-429.

3267. K.T. Nguyen Ba-Charvet, K. Brose, V. Marillat, T. Kidd, C.S. Goodman, M. Tessier-Lavigne, C. Sotelo, A. Chedotal, “Slit2-mediated chemorepulsion and collapse of developing forebrain axons,” Neuron 22(March 1999):463-473.

3268. H.S. Li et al, “Vertebrate Slit, a secreted ligand for the transmembrane protein roundabout, is a repellent for olfactory bulb axons,” Cell 96(19 March 1999):807-818.

3269. M. Hattori, M. Osterfield, J.G. Flanagan, “Regulated cleavage of a contact-mediated axon repellent,” Science 289(25 August 2000):1360-1365.

3270. B. Monschau et al, “Shared and distinct functions of RAGS and ELF-1 in guiding retinal axons,” EMBO J. 16(17 March 1997):1258-1267.

3271. Y. Shiratori, K. Hai, H. Takada, H. Kiriyama, T. Nagura, K. Matsumoto, K. Kamii, K. Otano, “Mechanism of accumulation of macrophages in galactosamine-induced liver injury: effect of lipoxygenase inhibitors on chemotaxis of spleen cells,” Pathobiology 60(1992):316-321.

3272. C.L. Hu, F.S. Barnes, “A theory of necrotaxis,” Biophys. J. 10(October 1970):958-969.

3273. M. Bessis, “Necrotaxis. Chemotaxis towards an injured cell,” Antibiot. Chemother. 19(1974):369-381.

3274. H. Gruler, “Necrotaxis and galvanotaxis,” Methods Enzymol. 162(1988):115-127.

3275. R. Ragot, “Negative necrotaxis,” Blood Cells 19(1993):81-88, 88-90 (discussion).

3276. M. Lind, M.C. Trindade, Y. Nakashima, D.J. Schurman, S.B. Goodman, L. Smith, “Chemotaxis and activation of particle-challenged human monocytes in response to monocyte migration inhibitory factor and C-C chemokines,” J. Biomed. Mater. Res. 48(1999):246-250; A. Hermanowski-Vosatka, S.S. Mundt, J.M. Ayala, S. Goyal, W.A. Hanlon, R.M. Czerwinski, S.D. Wright, C.P. Whitman, “Enzymatically inactive macrophage migration inhibitory factor inhibits monocyte chemotaxis and random migration,” Biochemistry 38(28 September 1999):12841-12849.

3277. J. Nishihira, “Macrophage migration inhibitory factor (MIF): its essential role in the immune system and cell growth,” J. Interferon Cytokine Res. 20(September 2000):751-762; “Novel pathophysiological aspects of macrophage migration inhibitory factor,” Int. J. Mol. Med. 2(July 1998):17-28.

3278. Y. Sibille, W.W. Merrill, G.P. Naegel, S.B. Care, J.A. Cooper Jr., H.Y. Reynolds, “Human alveolar macrophages release a factor that inhibits phagocyte function,” Am. J. Respir. Cell Mol. Biol. 1(November 1989):407-416.

3279. H. Donabedian, J.I. Gallin, “Mononuclear cells from patients with the hyperimmunoglobulin E-recurrent infection syndrome produce an inhibitor of leukocyte chemotaxis,” J. Clin. Invest. 69(May 1982):1155-1163.

3280. S. Chikazawa, H. Nunoi, F. Endo, I. Matsuda, M. Honda, “Hyperimmunoglobulin-E-associated recurrent infection syndrome accompanied by chemotactic inhibition of polymorphonuclear leukocytes and monocytes,” Pediatr. Res. 18(April 1984):365-369.

3281. T. Ruutu, P. Ruutu, P. Vuopio, K. Franssila, E. Linder, “An inhibitor of chemotaxis and phagocytosis in reticulum cell sarcoma,” Scand. J. Haematol. 15(August 1975):27-34.

3282. M. Hinder, “Investigation on the effect of experimental phospholipase A2 inhibitors on the formyl-methionyl-leucyl-phenylalanine-stimulated chemotaxis of human leukocytes in vitro,” Arzneimittelforschung 48(January 1998):77-81.

3283. G. Cohen, M. Rudnicki, W.H. Horl, “A peptide isolated from a patient on continuous ambulatory peritoneal dialysis has homology to ubiquitin and inhibits the chemotactic response of polymorphonuclear leukocytes,” Miner. Electrolyte Metab. 23(1997):210-213.

3284. J. Jongstra-Bilen, V.L. Misener, C. Wang, H. Ginzberg, A. Auerbach, A.L. Joyner, G.P. Downey, J. Jongstra, “LSP1 modulates leukocyte populations in resting and inflamed peritoneum,” Blood 96(1 September 2000):1827-1835.

3285. J.D. Walters, T.J. Miller, A.C. Cario, F.M. Beck, P.T. Marucha, “Polyamines found in gingival fluid inhibit chemotaxis by human polymorphonuclear leukocytes in vitro,” J. Periodontol. 66(April 1995):274-278.

3286. S. Spika, I. Dey, C. Buda, J. Csongor, G. Szegedi, T. Farkas, “The mechanism of inhibitory effect of eicosapentaenoic acid on phagocytic activity and chemotaxis of human neutrophil granulocytes,” Clin. Immunol. Immunopathol. 79(June 1996):224-228.

3287. W. Pruzanski, S. Saito, “Modulation of functional activity of human polymorphonuclear and mononuclear phagocytes by intravenous gamma globulin,” Inflammation 13(June 1989):341-357.

3288. D.E. Van Epps, B.R. Andersen, “Streptolysin O inhibition of neutrophil chemotaxis and mobility: nonimmune phenomenon with species specificity,” Infect. Immun. 9(January 1974):27-33; “Suppression of chemotactic activity of human neutrophils by streptolysin O,” J. Infect. Dis. 125(April 1972):353-359.

3289. Alan Kennedy, “Immune evasion by bacteria”;

3290. J. Rallof, J.H. Braconier, C. Soderstrom, P. Nilsson-Ehle, “Interference of Staphylococcus aureus lipase with human granulocyte function,” Eur. J. Clin. Microbiol. Infect. Dis. 7(August 1988):505-510.

3291. S. Utsumi, S. Sonoda, T. Imagawa, M. Kanoh, “Polymorphonuclear leukocyte-inhibitory factor of Bordetella pertussis. I. Extraction and partial purification of phagocytosis- and chemotaxis-inhibitory activities,” Biken. J. 21(December 1978):121-135.

3292. P.A. Ward, H.F. Dvorak, S. Cohen, T. Yoshida, R. Data, S.S. Selvaggio, “Chemotaxis of basophils by lymphocyte-dependent and lymphocyte-independent mechanisms,” J. Immunol. 114(May 1975):1523-1531.

3293. B. Van Vlem, R. Vanholder, P. De Paepe, D. Vogelaers, S. Ringoir, “Immunomodulating effects of antibiotics: literature review,” Infection 24(July-August 1996):275-291.

3294. P.J. van den Broek, “Antimicrobial drugs, microorganisms, and phagocytes,” Rev. Infect. Dis. 11(March-April 1989):213-245.

3295. D.H. Adams, L.F. Wang, J.M. Neuberger, E. Elias, “Inhibition of leukocyte chemotaxis by immunosuppressive agents. Specific inhibition of lymphocyte chemotaxis by cyclosporine,” Transplantation 50(November 1990):845-850.

3296. J.L. Salyer, J.F. Bohnsack, W.A. Knape, A.O. Shigeoka, E.R. Ashwood, H.R. Hill, “Mechanisms of tumor necrosis factor-alpha alteration of PMN adhesion and migration,” Am. J. Pathol. 136(April 1990):831-841.

3297. G. Vasanthakumar, R. Manjunath, A.B. Mukherjee, H. Warabi, E. Schiffmann, “Inhibition of phagocyte chemotaxis by uteroglobin, an inhibitor of blastocyst rejection,” Biochem. Pharmacol. 37(1 February 1988):389-394.

3298. F.P. Lindberg, H.D. Gresham, M.I. Reinhold, E.J. Brown, “Integrin-associated protein immunoglobulin domain is necessary for efficient vitronectin bead binding,” J. Cell Biol. 134(September 1996):1313-1322.

3299. P. Sacerdote, P. Massi, A.E. Panerai, D. Parolaro, “In vivo and in vitro treatment with the synthetic cannabinoid CP55,940 decreases the in vitro migration of macrophages in the rat: involvement of both CB1 and CB2 receptors,” J. Neuroimmunol. 109(22 September 2000):155-163.


Last updated on 16 April 2004